Management of Indolent Lymphoma: Where Are We Now and Where Are We Going

Por Lunning, Matthew, Vose, Julie M.
Publicado em 2012

Novel Treatment for Mantle Cell Lymphoma including Therapy-resistant Tumor by NF-κB and mTOR Dual Targeting Approach

Por Chaturvedi, Nagendra K., Rajule, Rajkumar N., Shukla, Ashima, Radhakrishnan, Prakash, Todd, Gordon L., Natarajan, Amarnath, Vose, Julie M., Joshi, Shantaram S.
Publicado em 2013

Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma

Por Timmerman, John M., Vose, Julie M., Czerwinski, Debra K., Weng, Wen-Kai, Ingolia, Diane, Mayo, Martha, Denney, Dan W., Levy, Ronald
Publicado em 2009

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20 + indolent NHL: Correlation between clinical responses and AUC pharmac...

Por Casulo, Carla, Vose, Julie M., Ho, William Y., Kahl, Brad, Brunvand, Mark, Goy, Andre, Kasamon, Yvette, Cheson, Bruce, Friedberg, Jonathan W.
Publicado no Clin Immunol (2014)

Autologous vs. Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response or...

Por Tomblyn, Marcie R., Ewell, Marian, Bredeson, Christopher, Kahl, Brad S., Goodman, Stacey A., Horowitz, Mary M., Vose, Julie M., Negrin, Robert S., Laport, Ginna G.
Publicado em 2010

Atrazine and Nitrate in Public Drinking Water Supplies and Non-Hodgkin Lymphoma in Nebraska, USA

Por Rhoades, Martha G., Meza, Jane L., Beseler, Cheryl L., Shea, Patrick J., Kahle, Andy, Vose, Julie M., Eskridge, Kent M., Spalding, Roy F.
Publicado em 2013

Survival Disparities in Patients With Lymphoma According to Place of Residence and Treatment Provider: A Population-Based Study

Por Loberiza, Fausto R., Cannon, Anthony J., Weisenburger, Dennis D., Vose, Julie M., Moehr, Matt J., Bast, Martin A., Bierman, Philip J., Bociek, R. Gregory, Armitage, James O.
Publicado em 2009

Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas

Por Bi, Chengfeng, Zhang, Xuan, Lu, Ting, Zhang, Xiaoyan, Wang, Xianhuo, Meng, Bin, Zhang, Huilai, Wang, Ping, Vose, Julie M., Chan, Wing C., McKeithan, Timothy W., Fu, Kai
Publicado no Haematologica (2017)

Immune Reconstitution after Autologous Hematopoietic Transplantation with Lin(−), CD34(+), Thy-1(LO) Selected or Intact Stem Cell Products

Por Singh, Rakesh K., Varney, Michelle L., Leutzinger, Cheryl, Vose, Julie M., Bierman, Philip J., Buyukberber, Suleyman, Ino, Kazuhiko, Loh, Kevin, Nichols, Craig, Inwards, David, Rifkin, Robert, Talmadge, James E.
Publicado em 2007

18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair

Por Wondergem, Marielle J, Herrmann, Ken, Syrbu, Sergei, Zijlstra, Josée M, Hoetjes, Nikie, Hoekstra, Otto S, Cillessen, Saskia AGM, Moesbergen, Laura M, Buck, Andreas K, Vose, Julie M, Juweid, Malik E
Publicado em 2014

Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transpl...

Por Vose, Julie M., Carter, Shelly, Burns, Linda J., Ayala, Ernesto, Press, Oliver W., Moskowitz, Craig H., Stadtmauer, Edward A., Mineshi, Shin, Ambinder, Richard, Fenske, Timothy, Horowitz, Mary, Fisher, Richard, Tomblyn, Marcie
Publicado em 2013

Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma

Por Fang, Nicole Y., Greiner, Timothy C., Weisenburger, Dennis D., Chan, Wing C., Vose, Julie M., Smith, Lynette M., Armitage, James O., Mayer, R. Aeryn, Pike, Brian L., Collins, Francis S., Hacia, Joseph G.
Publicado em 2003

Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-term Outcomes

Por van Besien, Koen, Carreras, Jeanette, Bierman, Philip J., Logan, Brent R., Molina, Arturo, King, Roberta, Nelson, Gene, Fay, Joseph W., Champlin, Richard E., Lazarus, Hillard M., Vose, Julie M., Hari, Parameswaran N.
Publicado em 2009

Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

Por Friedberg, Jonathan W., Taylor, Michael D., Cerhan, James R., Flowers, Christopher R., Dillon, Hildy, Farber, Charles M., Rogers, Eric S., Hainsworth, John D., Wong, Elaine K., Vose, Julie M., Zelenetz, Andrew D., Link, Brian K.
Publicado em 2009

CELL-OF-ORIGIN FAILS TO PREDICT SURVIVAL IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

Por Gu, Keni, Weisenburger, Dennis D, Fu, Kai, Chan, Wing C, Greiner, Timothy C, Aoun, Patricia, Smith, Lynette M, Bast, Martin, Liu, Zhongfen, Bociek, R. Gregory, Bierman, Philip J, Armitage, James O, Vose, Julie M
Publicado no Hematol Oncol (2011)

Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project

Por Federico, Massimo, Rudiger, Thomas, Bellei, Monica, Nathwani, Bharat N., Luminari, Stefano, Coiffier, Bertrand, Harris, Nancy L., Jaffe, Elaine S., Pileri, Stefano A., Savage, Kerry J., Weisenburger, Dennis D., Armitage, James O., Mounier, Nicholas, Vose, Julie M.
Publicado em 2013

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Por Friedberg, Jonathan W., Vose, Julie M., Kelly, Jennifer L., Young, Faith, Bernstein, Steven H., Peterson, Derick, Rich, Lynn, Blumel, Susan, Proia, Nicole K., Liesveld, Jane, Fisher, Richard I., Armitage, James O., Grant, Steven, Leonard, John P.
Publicado em 2011

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

Por Meyer, Paul N., Fu, Kai, Greiner, Timothy C., Smith, Lynette M., Delabie, Jan, Gascoyne, Randy D., Ott, German, Rosenwald, Andreas, Braziel, Rita M., Campo, Elias, Vose, Julie M., Lenz, Georg, Staudt, Louis M., Chan, Wing C., Weisenburger, Dennis D.
Publicado em 2011

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Por Friedberg, Jonathan W., Sharman, Jeff, Sweetenham, John, Johnston, Patrick B., Vose, Julie M., LaCasce, Ann, Schaefer-Cutillo, Julia, De Vos, Sven, Sinha, Rajni, Leonard, John P., Cripe, Larry D., Gregory, Stephanie A., Sterba, Michael P., Lowe, Ann M., Levy, Ronald, Shipp, Margaret A.
Publicado em 2010

UNRELATED DONOR REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA

Por Devetten, Marcel P., Hari, Parameswaran N., Carreras, Jeanette, Logan, Brent R., van Besien, Koen, Bredeson, Christopher N., Freytes, César O., Peter Gale, Robert, Gibson, John, Giralt, Sergio A., Goldstein, Steven C., Gupta, Vikas, Marks, David I., Maziarz, Richard T., Vose, Julie M., Lazarus, Hillard M., Anderlini, Paolo
Publicado em 2009